Antimicrobial resistance: what is pharma doing?
This article was originally published in Scrip
Executive Summary
The UK recently saw the launch of a five-year antimicrobial resistance strategy, an initiative which will see it work with organizations across the globe to tackle a problem that almost everyone saw coming, but few have been able to do much about. While many initially expected the pharma industry to exploit the problem with innovative new antimicrobials, the reality has been that pharma companies have been forced to scale down their antimicrobial efforts or bow out of the area. Scrip spoke to Dr Catriona McMahon, AstraZeneca's director of UK medical and healthcare affairs, to find out why.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.